These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16974073)

  • 1. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711).
    Peppa M; Brem H; Cai W; Zhang JG; Basgen J; Li Z; Vlassara H; Uribarri J
    Am J Nephrol; 2006; 26(5):430-6. PubMed ID: 16974073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products.
    Zheng F; He C; Cai W; Hattori M; Steffes M; Vlassara H
    Diabetes Metab Res Rev; 2002; 18(3):224-37. PubMed ID: 12112941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective antioxidant effect of alagebrium in experimental diabetes.
    Park J; Kwon MK; Huh JY; Choi WJ; Jeong LS; Nagai R; Kim WY; Kim J; Lee GT; Lee HB; Ha H
    Nephrol Dial Transplant; 2011 Nov; 26(11):3474-84. PubMed ID: 21478303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
    Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
    Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats.
    Nakamura S; Tachikawa T; Tobita K; Aoyama I; Takayama F; Enomoto A; Niwa T
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S68-71. PubMed ID: 12612956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective effects of a novel inhibitor of advanced glycation.
    Forbes JM; Soulis T; Thallas V; Panagiotopoulos S; Long DM; Vasan S; Wagle D; Jerums G; Cooper ME
    Diabetologia; 2001 Jan; 44(1):108-14. PubMed ID: 11206401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
    Coughlan MT; Thallas-Bonke V; Pete J; Long DM; Gasser A; Tong DC; Arnstein M; Thorpe SR; Cooper ME; Forbes JM
    Endocrinology; 2007 Feb; 148(2):886-95. PubMed ID: 17110423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
    Loeffler I; Rüster C; Franke S; Liebisch M; Wolf G
    Am J Physiol Renal Physiol; 2013 Sep; 305(6):F911-8. PubMed ID: 23825071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal increases in urinary carboxymethyllysine correlate with albuminuria development in diabetes.
    Coughlan MT; Forbes JM
    Am J Nephrol; 2011; 34(1):9-17. PubMed ID: 21654162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.
    Tan AL; Sourris KC; Harcourt BE; Thallas-Bonke V; Penfold S; Andrikopoulos S; Thomas MC; O'Brien RC; Bierhaus A; Cooper ME; Forbes JM; Coughlan MT
    Am J Physiol Renal Physiol; 2010 Mar; 298(3):F763-70. PubMed ID: 20015941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats.
    Gurbuz N; Sagdic G; Sanli A; Ciftcioglu A; Bassorgun I; Baykal A; Usta MF
    Int J Impot Res; 2012; 24(3):114-21. PubMed ID: 22205245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
    Williams ME; Bolton WK; Khalifah RG; Degenhardt TP; Schotzinger RJ; McGill JB
    Am J Nephrol; 2007; 27(6):605-14. PubMed ID: 17823506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.
    Sebeková K; Gazdíková K; Syrová D; Blazícek P; Schinzel R; Heidland A; Spustová V; Dzúrik R
    J Hum Hypertens; 2003 Apr; 17(4):265-70. PubMed ID: 12692571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of phlorizin on diabetic nephropathy in diabetic db/db mice.
    Pei F; Li BY; Zhang Z; Yu F; Li XL; Lu WD; Cai Q; Gao HQ; Shen L
    J Diabetes Complications; 2014; 28(5):596-603. PubMed ID: 24927646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes.
    Nakamura N; Yamazaki K; Satoh A; Urakaze M; Kobayashi M; Yamabe H; Osawa H; Shirato K; Sugawara T; Nakamura M; Tamura M; Okumura K
    In Vivo; 2003; 17(2):177-80. PubMed ID: 12792982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
    Thallas-Bonke V; Thorpe SR; Coughlan MT; Fukami K; Yap FY; Sourris KC; Penfold SA; Bach LA; Cooper ME; Forbes JM
    Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.